Outpace Bio

Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.

It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.

Outpace Bio headquartered in United States, North America, operates in the Biotechnology, Life Science, Health Care, Pharmaceutical sector. The company focuses on Biotechnology and has secured $9.6B in funding across 48 round(s). With a team of 51-100 employees, Outpace Bio is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Outpace Bio, raised $144.0M. Discover more about their projects, partnerships, and impact on our platform.